Table 1.
Patient characteristics (n = 110): no significant difference in age, KPS, number of brain metastases, extracranial metastases, primary tumour control, DS-GPA and RPA classification, radiation dose, and time interval (P = 0.22 or more); significant difference: primary disease type (P = 0.03).
| Parameter | Interval < 12 days | Interval ≥ 12 days |
|---|---|---|
| Median age, years | 64 | 64 |
| Median KPS | 60 | 70 |
| Median DS-GPA score (min. 0, max. 4 points) | 1.0 | 1.0 |
| Number of BM: 1 (%) | 5 | 9 |
| Number of BM: 2-3 (%) | 17 | 16 |
| Number of BM: >3 (%) | 25 | 27 |
| Extracranial metastases (%) | 43 | 38 |
| No extracranial metastases (%) | 5 | 15 |
| Uncontrolled primary tumour (%) | 16 | 25 |
| Controlled primary tumour (%) | 31 | 28 |
| DS-GPA class I versus II versus III versus IV (%) | 2, 4, 9, 33 | 1, 5, 17, 30 |
| RPA class I versus II versus III (%) | 2, 20, 25 | 3, 26, 24 |
| NSCLC, SCLC (%) | 15, 8 | 32, 2 |
| Breast, MM, and GI (%) | 9, 3, 6 | 3, 4, 6 |
| Kidney, others (%) | 4, 2 | 4, 3 |
| Total dose 20 Gy (%) | 12 | 17 |
| Total dose 30 Gy (%) | 35 | 35 |
| Simultaneous detection of BM and primary tumour (%) | 8 | 17 |
| Time interval to BM 1–12 months (%) | 23 | 17 |
| Time interval to BM 13–36 months (%) | 7 | 9 |
| Time interval to BM > 36 months (%) | 9 | 8 |
KPS: Karnofsky performance status; BM: brain metastases; DS-GPA: diagnosis-specific graded prognostic assessment; NSCLC: nonsmall cell lung cancer; SCLC: small cell lung cancer; MM: malignant melanoma; GI: gastrointestinal primary tumour.